Dear Molecular Imaging Insider,
A group of researchers from Austria and the U.S. is reporting success with PET imaging with the use of a novel gallium-68-labeled prostate-specific membrane antigen (PSMA) conjugated ligand for detecting disease recurrence after radical prostatectomy.
PSMA-PET advanced the detection of recurrent prostate cancer at relatively low PSA levels and altered treatment management for 75% of the patients in this study. For more details, click here.
In a second article posted today, we report the latest news about the National Health Service England PET-CT Clinical Audit Programme. This government initiative was introduced in 2008, and after two comprehensive surveys, a series of important lessons can be learned from its first decade. Find out more here.
We also feature a remarkable study from France, where researchers were able to restore consciousness to a patient who had been comatose for 15 years. They were able to achieve that goal with the help of PET and electroencephalography (EEG) to confirm the efficacy of vagus nerve stimulation.
Ignore cardiac FDG uptake in oncological PET/CT at your peril. That's the key message of new research presented at the recent European Society of Cardiovascular Radiology congress in Milan. The study also emphasized MRI as a useful technique for evaluating complex cases and helping to differentiate between benign and malignant lesions.
In addition, another group of French researchers is promoting FDG-PET/CT and the hybrid modality's ability to assess response to treatment and redirect therapy for patients with recurrent or progressive anal cancer.
And, finally, what could champagne and PET/MRI possibly have in common? This fascinating article takes a look at the origins of champagne and integrated PET/MRI and compares them.
Be sure to visit the Molecular Imaging Community on a daily basis to stay informed of the latest news and research from around the continent and the world.
